Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the ...
IBD is rising worldwide and is now a global disease. With the expanding armamentarium of medical therapies, including biologics and small molecules, there is a decline in hospitalisation rates and IBD ...
Investor's Business Daily on MSN
Zeta Global Holdings earns membership in 95-plus composite rating club
On Monday, Zeta Global Holdings ZETA got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. Please watch the ...
Dr. Mahadevan discusses newly issued GCC guidance developed to improve the management of pregnancy for patients with IBD.
In addition, $14B Mather Group acquires a New Jersey-based firm, Prime Capital recruits an established RPA, and EY analysts ...
International study of microbiome data finds loss of beneficial bacteria and increase in bacteria from mouth lower in the gut ...
According to DataM Intelligence, the global Inflammatory Diseases Biologics Market was valued at USD 99.06 billion in 2024 and is projected ...
Investor's Business Daily on MSN
Dow Jones futures fall after market retreats; Google leads AI stocks in buy zones
Dow Jones futures edged lower overnight, along with S&P 500 futures and Nasdaq futures.Wells FargoWFC, CitigroupC and Bank of ...
Dr Ray O’Connor takes a look at recent clinical articles on Diet and GI Issues, including the effects of caffeine, ...
Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics ...
Halozyme Therapeutics Inc. has entered into a global collaboration and exclusive license agreement with Takeda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback